Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-18
2006-04-18
Landsman, Robert S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S970000, C424S085100, C424S085200, C424S085400, C424S085700, C530S350000, C530S351000
Reexamination Certificate
active
07030086
ABSTRACT:
Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.
REFERENCES:
patent: 4812557 (1989-03-01), Yasushi et al.
patent: 4883661 (1989-11-01), Daly et al.
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4931543 (1990-06-01), Halenbeck et al.
patent: 5078997 (1992-01-01), Hora et al.
patent: 5272135 (1993-12-01), Takruri
patent: 5340574 (1994-08-01), Maneglier et al.
patent: 5358708 (1994-10-01), Patel
patent: 5744132 (1998-04-01), Warne et al.
patent: 5763395 (1998-06-01), Blackburn et al.
patent: 5795779 (1998-08-01), McCormick et al.
patent: 0 229 016 (1987-07-01), None
patent: 0 303 746 (1993-02-01), None
patent: 921124 (1992-10-01), None
patent: WO 96/40784 (1996-12-01), None
patent: WO 99/51272 (1999-10-01), None
Allen et al., “Hybrid (BDBB) Interferon-Alpha.: Preformulation Studies,”Int J Pharm, 1999, pp. 259-272, vol. 187.
Chang et al., “Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist,”Pharmaceutical Research, 1996, pp. 243-249, vol. 13.
Chen et al., “Solubility of Recombinant Human Tissue Factor Pathway Inhibitor,”Journal of Pharmaceutical Sciences, 1999, pp. 881-888, vol. 88.
Heller et al., “Manipulation of Lypphilization-Induced Phase Separation: Implications for Pharmaceutical Proteins,”Biotechnol Prog., 1997, pp. 590-596, vol. 13.
Taneja et al., “Increased Therami Stability of Proteins in the Presence of Amino Acids,”Biochem J., 1994, pp. 147-153, vol. 303.
Wang et al., “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,”Journal of Parenteral Science and Technology, 1988, pp. S1-S26, vol. 42.
Chen Bao-Lu
Hora Maninder S.
Chappell Cherie M.
Chiron Corporation
Harbin Alisa A.
Hemmendinger Lisa M.
Landsman Robert S.
LandOfFree
Stabilized liquid polypeptide-containing pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized liquid polypeptide-containing pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized liquid polypeptide-containing pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532888